^
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1wk
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive
:
A1
FDA - 2wk
IKZF1 deletion + IKZF3 deletion
Diffuse Large B Cell Lymphoma
CC-122
Sensitive
:
C4
Blood Adv - 3wk
IKZF1 G151A overexpression
Diffuse Large B Cell Lymphoma
CC-122
Resistant
:
C4
Blood Adv - 3wk
IKZF3 G152A overexpression
Diffuse Large B Cell Lymphoma
CC-122
Resistant
:
C4
Blood Adv - 3wk
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
NHL
brentuximab vedotin
Sensitive
:
A1
ALK positive
NHL
crizotinib
Sensitive
:
C1
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive
:
C1
No biomarker
Burkitt Lymphoma
cyclophosphamide intravenous
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
ICP-022
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
ICP-022
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
A1
CD20 expression
NHL
rituximab-arrx
Sensitive
:
C1
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
NHL
carmustine
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Truxima (rituximab biosimilar)
Sensitive
:
C1
No biomarker
Follicular Lymphoma
Truxima (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Ruxience (rituximab biosimilar)
Sensitive
:
C1
No biomarker
Follicular Lymphoma
Ruxience (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our